Vertex Pharma has teamed up with Orum Therapeutics to develop a conditioning regimen, used to prepare patients to receive gene-editing medicines, that it hopes will offer a more tolerable ...

Orum Therapeutics sets public offering price at 20,000 won, below target range Orum Therapeutics announces lower-than-expected public offering price as subscription period approaches ...

Bristol-Myers Squibb has signed another deal to build its capabilities in antibody-drug conjugates for cancer, paying $100 million upfront to take control of an Orum Therapeutics candidate with a ...

Vertex Pharmaceuticals and Orna Therapeutics have announced a three ... In July 2024, it invested $15m in South Korea's Orum to acquire technology aimed at making preconditioning more tolerable.